Brokerages forecast that OptimizeRx Corp. (NYSE:OPRX) will post $0.01 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for OptimizeRx’s earnings, with the highest EPS estimate coming in at $0.02 and the lowest estimate coming in at $0.00. OptimizeRx reported earnings of ($0.06) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 116.7%. The business is expected to report its next quarterly earnings report after the market closes on Monday, November 5th.

On average, analysts expect that OptimizeRx will report full year earnings of $0.02 per share for the current fiscal year, with EPS estimates ranging from ($0.02) to $0.05. For the next year, analysts anticipate that the firm will post earnings of $0.21 per share, with EPS estimates ranging from $0.15 to $0.27. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for OptimizeRx.

OptimizeRx (NYSE:OPRX) last posted its quarterly earnings results on Tuesday, August 7th. The company reported $0.02 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.02) by $0.04. The company had revenue of $5.10 million during the quarter, compared to analyst estimates of $4.34 million.

Separately, B. Riley reissued a “buy” rating on shares of OptimizeRx in a research note on Tuesday, July 10th.

OPRX stock opened at $15.96 on Monday. OptimizeRx has a 52 week low of $2.30 and a 52 week high of $18.39.

About OptimizeRx

OptimizeRx Corporation provides digital health messaging to the pharmaceutical industry. The company offers a direct channel for pharmaceutical companies to communicate with healthcare providers. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-Prescribe systems to search, print, or electronically dispense directly to patients, as well as a network of pharmacies; and brand messaging services, such as various brand awareness and clinical messaging services consisting of brand awareness messages, reminder ads, clinical messages, and unbranded messages that could be targeted by specialty, diagnostic code, and other criteria.

Featured Story: Marijuana Stocks Future Looks Bright

Get a free copy of the Zacks research report on OptimizeRx (OPRX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with's FREE daily email newsletter.